CHATTANOOGA, Tenn., Feb. 28, 2011 /PRNewswire/ — Glenveigh
Medical, LLC and Monica Healthcare Limited today announced an
agreement for exclusive distribution rights in the United States as
well as US territories and military bases for Monica Healthcare’s
AN24 wireless fetal monitoring system. The system recently received
FDA regulatory clearance for use during labor and delivery.
Marketed under the trade name Beacon by Monica™, the
wireless fetal monitoring system will be available in U.S.
hospitals exclusively through Glenveigh and promoted by Glenveigh’s
sales and distribution partner Norgenix Pharmaceuticals, LLC.
Glenveigh is a life science and technology company
focused on advancing the practice of obstetrics worldwide. United
Kingdom-based Monica Healthcare develops wireless technologies for
use in obstetrics.
“We are pleased to announce our partnership with Monica,” stated
C. David Adair, M.D., Founder, Chairman, and Chief Scientific
Officer of Glenveigh Medical. “The Beacon by Monica™
is a break-though wireless device that monitors the fetal heart
rate and uterine activity while allowing patients to ambulate
without the usual nurse intervention.”
Rick Proctor, President and CEO of Glenveigh Medical, added,
“The Monica AN24 technology was validated in a rigorous clinical
study that was reviewed by the FDA as part of the 510(k) clearance
process.”
The Beacon by Monica™ is simple to use, beltless,
requires no wires to connect to a display or printer, and is
designed to provide high levels of patient satisfaction. There is
no need for the constant re-positioning of transducers which is
required with current technology. Clinical trials also demonstrated
that the device performs well in obese women where use of
conventional technology can be challenging.
“This technology has already generated a tremendous amount of
excitement and interest,” stated Jeff Bradford, VP of Marketing
for
‘/>”/>
